If you’re paying attention this week, AbbVie’s name keeps showing up in our coverage.
They took an option-to-acquire warrant on Kestrel Therapeutics for a pan-KRAS program. And on the same news cycle, EvolveImmune Therapeutics announced it had hit the first development candidate milestone in its 2024 collaboration with AbbVie, triggering an $18 million payment to the Branford, Connecticut company.
$18 million is a discrete data point.
The original October 2024 deal between EvolveImmune and AbbVie was $65 million upfront and equity, with up to $1.4 billion in option fees and milestones across the partnership, plus tiered royalties.
EvolveImmune just collected on the first milestone tranche by nominating a development candidate from the platform.
First time the structure has paid out.
Why does AbbVie keep choosing this deal architecture?
I thinks its because it essentially lets them rent platforms instead of buying them. They get optionality on programs as they de-risk, without taking dilution onto the parent’s pipeline until the molecule looks like a drug.
And in immuno-oncology, where conviction in any given mechanism shifts every six months, optionality is more valuable than ownership.
And before you go off thinking that this is just your average run-of-the-mill BiTE, the EVOLVE platform itself is doing something genuinely different…sort of.
It’s producing trispecific T cell engagers that hit i) tumor antigen, ii) CD3, and iii) CD2 simultaneously.
The CD2 engagement is the real meat and potatoes.
Conventional CD3 bispecific engagers like blinatumomab and the BiTE class drove huge wins in heme malignancies, but they exhaust T cells, trigger cytokine storms, and tend to flame out in low-immunogenicity solid tumors.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
Adding CD2 costimulation directly into the molecule, the EvolveImmune team is trying to give T cells the second signal they normally only get when antigen-presenting cells reinforce the T cell receptor encounter.
Their preclinical data suggests this drives more sustained killing, less exhaustion, and better penetration into solid tumors. It is a thesis that has been kicked around for years; EvolveImmune is the one with the clinical-stage molecule.
That molecule, EVOLVE104, dosed its first patient in December 2025 in advanced urothelial and squamous cell carcinomas, two tumor types where T cell engagers have historically failed.
Up to 160 patients are planned.
NSCLC, head and neck, and bladder are the lead indications.
The pipeline behind EVOLVE104 is intense.
EVOLVE-105 for refractory B cell lymphoma.
EVOLVE-106 for solid tumors.
EVOLVE-101 for B cell and myeloid malignancies.
EVOLVE205, a next-gen format.
Plus whatever AbbVie is now developing under the partnership.
EvolveImmune emerged from stealth in 2025 with $103M raised across Pfizer Ventures, Solasta, Takeda, and Bristol Myers Squibb as a strategic. The AbbVie deal sits on top. Now CEO Stephen Bloch’s team has its first cash milestone, plus a pharma partner publicly committed to advancing the program.
Two AbbVie deals on the same news cycle.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
